Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2022

View Archived Issues

Researchers present CX-10759 anti-IgE antibody for hypersensitivity

RUNX1 targeting shows promise for treating aggressive PDAC

Sitryx Therapeutics describes nuclear factor erythroid 2-related factor 2 activators

New SLC10A2/SLC10A1 inhibitors identified at Albireo

Ruhr University Bochum presents new compounds for treating axonal damage

Roche divulges new TLR7/8/9 antagonists

Eoetvoes Lorand Tudomanyegyetem, Semmelweis University patent imipridone derivatives

Immunotherapies targeting WT137-45 may avoid acute myeloid leukemia immune evasion

BBP-671 restores brain glutamate/glutamine levels in preclinical model of coenzyme A deficiency

Novel propolis-derived CREB/CRTC2 inhibitor ameliorates metabolic syndrome in obese mice

NTLA-2002 shows promising preclinical results in a partial hepatectomy-induced HAE model

RedCloud cleared to enter clinic with next-generation EGFR inhibitor H-002 for NSCLC

Novel IL-33-dependent mouse model of eosinophilic esophagitis

Adagene and Sanofi collaborate on masked monoclonal and bispecific antibodies for immuno-oncology

PMN-310 shows cognitive benefit in mouse model of Alzheimer's disease

9 Meters collaborates with NYU Langone Health to evaluate NM-102 for autoimmune disorder

Intranasal COVID-19 booster BW-1019 provides protection and boosts immune response in hamsters

Infection in thymus causes autoimmunity in stomach

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...